Patients' attitudes and perceptions towards treatment of hypothyroidism in general practice: an in-depth qualitative interview study by Dew, R. et al.
*For correspondence: rosie.dew@
sunderland.ac.uk
Competing interests: The
authors declare that no
competing interests exist.
Received: 27 February 2017
Accepted: 28 February 2017
Published: 28 June 2017
Author Keywords: general
practice, levothyroxine,
hypothyroidism, patient
attitudes, TSH
Copyright s 2017, British
Journal of General Practice;
DOI:10.3399/
bjgpopen17X100977
Patients’ attitudes and perceptions
towards treatment of hypothyroidism in
general practice: an in-depth qualitative
interview study
Rosie Dew, PhD1*, Kathryn King, PhD2, Onyebuchi E Okosieme, MD, FRCP3,
Simon Pearce, PhD, MD, FRCP4, Gemma Donovan, MSc5,
Peter Taylor, MSc, MBChB6, Graham Leese, MD, FRCP7, Janis Hickey, BA8,
Salman Razvi, MD, FRCP9, Colin Dayan, PhD, FRCP10, Scott Wilkes, PhD, FRCGP11
1Research Associate, Faculty of Health Sciences and Wellbeing, University of
Sunderland, Sunderland, UK; 2Principle Lecturer, Faculty of Sciences and Wellbeing,
University of Sunderland, Sunderland, UK; 3Consultant Endocrinologist and
Honorary Lecturer, Diabetes and Endocrinology Department, Prince Charles
Hospital, Cwm Taf Health Board, Cardiff, UK; 4Professor of Endocrinology, Institute
of Human Genetics, Newcastle University, Newcastle, UK; 5Academic Pharmacist
Practitioner, Faculty of Health Sciences and Wellbeing, University of Sunderland,
Sunderland, UK; 6Welsh Clinical Academic Trainee, Institute of Molecular and
Experimental Medicine, Cardiff University School of Medicine, Cardiff, UK;
7Consultant and Professor in Diabetes and Endocrinology, University of Dundee,
Ninewells Hospital and Medical School, Dundee, UK; 8Founder and Director, British
Thyroid Foundation, Harrogate, UK; 9Consultant Endocrinologist and Senior
Lecturer, Institute of Human Genetics, Newcastle University, Newcastle, UK;
10Professor of Clinical Diabetes and MetabolismInstitute of Molecular and
Experimental Medicine, Institute of Molecular and Experimental Medicine, Cardiff
University School of Medicine, Cardiff, UK; 11Professor of General Practice and
Primary Care, Faculty of Health Sciences and Wellbeing, University of Sunderland,
Sunderland, UK
Abstract
Background: Suboptimal thyroid hormone replacement is common in patients with hypothyroidism
and the behavioural factors underlying this are poorly understood.
Aim: To explore the attitudes and perceptions of patients to thyroid hormone replacement
therapy.
Design & setting: An in-depth qualitative interview study with patients with hypothyroidism
residing in Northumberland, and Tyne and Wear, UK.
Method: Twenty-seven patients participated, of which 15 patients had thyroid stimulating hormone
(TSH) levels within the reference range (0.4–4.0 mU/L) and 12 patients had TSH levels outside the
reference range. A grounded theory approach was used to explore and develop emerging themes,
which were mapped to the health belief model (HBM).
Results: Patients generally had a low understanding of their condition or of the consequences of
suboptimal thyroid hormone replacement. Patients that had experienced hypothyroid symptoms at
initial diagnosis had a better perception of disease susceptibility, and this was reflected in excellent
adherence to levothyroxine in this group of patients. The main benefits of optimal thyroid
Dew R et al. BJGP Open 2017; DOI: 10.3399/bjgpopen17X100977 1 of 13
RESEARCH
replacement were improved wellbeing and performance. However, patients who remained unwell
despite a normal serum TSH level felt that their normal result presented a barrier to further
evaluation of their symptoms by their GP.
Conclusion: Educating patients with hypothyroidism regarding the consequences of inadequate
thyroid hormone replacement may reduce barriers and improve treatment outcomes. An over-
reliance on TSH as a sole marker of wellbeing reduced opportunities for clinicians to address
patient symptoms. Evaluating symptoms in combination with biochemical indices, may lead to
better patient outcomes than relying on laboratory tests alone.
How this fits in
There is limited information on the behavioural factors that influence disease outcomes in patients
with hypothyroidism. This qualitative study of patients’ attitudes and perceptions shows that patients
generally adhered well to treatment but were often unable to obtain clear, reliable information
about their disease or its treatment. A TSH concentration within the reference range was perceived
by most patients to be an unsatisfactory measure of wellbeing that often precluded meaningful
interaction with their practitioners. Outcomes may be improved by the provision of better quality
information, together with a clinical approach that addresses patients’ symptoms and concerns,
alongside their biochemical indices of thyroid function.
Introduction
Hypothyroidism is a chronic condition affecting 2–5% of the population.1 About 3% of the UK popu-
lation receive levothyroxine therapy2 with the aim of treatment being to achieve patient wellbeing
and restore serum thyroid stimulating hormone (TSH) levels to within the reference range.3 Levothyr-
oxine is the third most dispensed drug in England with 29.7 million items dispensed in 2015 alone.4
After individual dose adjustment levothyroxine is generally well-tolerated and most patients continue
lifelong therapy without complications.5
Suboptimal replacement as shown by abnormal TSH levels, however, has remained problematic
for over 20 years,6,7 despite increasing regularity in the biochemical monitoring of patients.8–10
Patients with suboptimal replacement may have an increased risk of cardiovascular events and frac-
tures.11–13 Furthermore, women of childbearing age established on levothyroxine often have out-of-
range TSH levels at the time of conception, increasing the risk of adverse pregnancy outcomes.14
Reduced quality of life is common among patients with hypothyroidism, particularly relating to
energy, motivation, physical capabilities, physical appearance, and weight gain.15,16 In addition,
there are substantial healthcare resource implications of having abnormal TSH levels including repeat
laboratory testing, levothyroxine dose adjustments, and medicines wastage.
Potential causes of inadequate thyroid hormone replacement include medication adherence17,18
as well as biochemical,19 pharmacogenomic,20–23 and medication formulation factors.24 To date,
most guidance on managing thyroid hormone replacement has focused on physiological and phar-
macological factors.3,25 However, there is little information on behavioural factors even though
patient perception and attitudes towards their illness play a pivotal role in improving chronic disease
outcomes.26 To begin to address this problem this study explored the behavioural factors that may
contribute to suboptimal treatment in patients with hypothyroidism.
Method
Design
This study used in-depth qualitative interviews with patients with hypothyroidism to explore their
experiences, attitudes, and perceptions towards their treatment. A grounded approach was used to
develop emerging themes.27 The theoretical underpinning of the project was provided by the
HBM28 which has two main components; perceived threat and behavioural evaluation aspects.29 The
HBM enabled mapping of themes to give an overall explanation of patient’s ability and readiness to
influence the control of their disease.
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Participants
The National Institute for Health Research (NIHR) Clinical Research Network North East and North
Cumbria approached primary care practices in Northumberland and Tyne and Wear and nine agreed
to take part. On average, each GP practice sent 30 study packs containing an invitation letter and
information sheet to patients with overt hypothyroidism established on levothyroxine for 12
months. Around three patients per GP surgery chose to take part, while two patients approached
the researcher after hearing about the study during a presentation. Twenty-seven interviews were
conducted, of which 15 patients had TSH levels within the reference range (0.4–4.0 mU/L)3 and 12
had TSH levels outside the reference range. Participant characteristics are shown in Table 1.
Interviews were conducted by the same researcher. An initial semistructured topic guide was
used to explore questions related to the study and this was revised as the study progressed (Box 1).
Interviews lasted around 45 minutes with only the researcher and patient present, except on two
occasions when family members were present and contributed. Patients were given a £10 voucher
for their participation. All interviews were audiorecorded, transcribed verbatim, and anonymised.
The majority of interviews took place in the patient’s home with the exception of four patients who
preferred their GP surgery, two patients the University of Sunderland, and one patient their place of
work. Transcripts were returned to participants for comments and no patients asked for any
changes.
Sampling
Purposive sampling was used to initially identify participants from both rural and urban areas, and
large and small GP practices, resulting in a maximum variation sample.27 Theoretical sampling was
then used to test emerging categories and themes which proceeded until data saturation was
achieved.30
Analysis
Data collection and analysis were conducted in parallel. Interview data were initially open coded and
then analysed using constant comparison, allowing for generation or re-classification of themes. As
the interviews progressed, themes emerging from the data informed questioning in subsequent
interviews.31 Finally, selective coding was used to identify the core categories and themes.27 In-
depth data analysis was conducted by two researchers and a third researcher was involved in the
overall explanation of the data. Emergent themes were mapped to the constructs of the HBM
(Figure 1).
Results
Perceived threat of hypothyroidism: susceptibility and severity
Patient perception of threat of disease was strongly linked to their experience of symptoms prior to
diagnosis. Severe tiredness was the most commonly described symptom, while weight gain, dry
skin, ‘brain fog’, and scalp hair loss were less common:
’Well, it was at a point where I was just totally physically exhausted, you know. The 10-minute
walk to work that I had at the time was taking every ounce of energy. That’s how I put it to the
GP. And my brain was a fog as well. I couldn’t think straight at work.’ (Patient-22, male,
68 years old)
The patients that had not experienced symptoms prior to diagnosis were mostly unfamiliar with
the typical symptoms of hypothyroidism and perception of disease susceptibility and severity was
low:
’So, in a sense, I suppose I’ve become positively confidently complacent about what I still don’t
describe as a condition. As I didn’t have symptoms, other than the lumps which then led to the
subtotal [thyroidectomy], which then led to the replacement by chemicals, which continues and
hasn’t changed.’ (Pateint-23, male, 69 years old)
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Table 1 Patient demographics
Characteristic
Patients with TSH within
reference range
N = 15, n (%)
Patients with TSH lower than
reference range N = 7, n (%)
Patients with TSH higher than
reference range N = 5, n (%)
Sex Female 11 (73) 4 (57) 3 (60)
Male 4 (27) 3 (43) 2 (40)
Location Rural 6 (40) 6 (86) 1 (20)
Urban 9 (60) 1 (14) 4 (80)
Age, years 30–39 1 (7) 1 (14) 2 (40)
40–49 1 (7) 1 (14) 1 (20)
50–59 0 (0) 0 (0) 1 (20)
60–69 8 (53) 3 (43) 1 (20)
70–79 3 (20) 1 (14) 0 (0)
80–89 2 (13) 1 (14) 0 (0)
Years with
hypothyroidism
5 2 (13) 1 (14) 3 (60)
6–10 2 (13) 4 (57) 0 (0)
11–20 5 (33) 1 (14) 2 (40)
>20 6 (40) 1 (14) 0 (0)
Other relevant
health
conditions
Coeliac disease 0 (0) 0 (0) 0 (0)
Pernicious anaemia 2 (13) 0 (0) 0 (0)
Gastrointestinal
(gallstones/diverticulitis/
irritable bowel syndrome/twisted
bowel/constipation)
4 (27) 2 (29) 2 (40)
Type 2 diabetes 3 (20) 0 (0) 0 (0)
Other relevant
medications
Calcium-containing drugs 3 (20) 0 (0) 1 (20)
Iron-containing drugs 0 (0) 1 (14) 1 (20)
Proton pump inhibitors 3 (20) 1 (14) 1 (20)
BMI <20 1 (7) 0 0
20–25 5 (33) 1 (14) 2 (40)
26–30 5 (33) 5 (71) 2 (40)
31–35 3 (20) 1 (14) 1 (20)
36–40 1 (7) 0 0
Daily
levothyroxine
dose, mg
25 1 (7) 0 0
50 1 (7) 0 0
75 2 (13) 0 0
100 3 (20) 2 (29) 2 (40)
125 3 (20) 2 (29) 3 (60)
150 2 (13) 0 0
175 0 (0) 0 0
200 0 (0) 0 0
225 0 (0) 1 (14) 0
100/125 alternate day dosing 1 (7) 1 (14) 0
100/75 alternate day dosing 0 (0) 1 (14) 0
100 Monday–Friday, 75 Saturday–
Sunday
2 (13) 0 0
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Perception of threat of disease was demonstrated by reported adherence to treatment, and
patients felt they needed to take their levothyroxine to prevent the symptoms of hypothyroidism.
Only one interviewee who had serum TSH levels within the reference range reported forgetting ther
Box 1. Initial topic guide for patient interviews
. What do you think about the control of your hypothyroidism?
. Are you well controlled or poorly controlled?
. How often do you get your thyroid blood tests checked?
. How often do you feel you should have your blood test checked?
. How do you get your results?
. Are you aware of how well/poorly you are controlled?
. What do you understand about how your thyroid is controlled?
. Are you aware of any consequences of poor control?
. What are the symptoms of being out of control?
. How much of your life do you feel well controlled?
. Do you ever forget to take your tablets? If so what do you do?
. What else do you think may influence the control of your hypothyroidism?
Figure 1. Concept diagram of categories and themes from interviews. TSH = thyroid stimulting hormone.
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medication at weekends as they kept their levothyroxine at work, while one patient with out of range
TSH regularly forgot to take their tablets as they were trying to avoid taking them with food:
’Because I don’t want to be like I was before I didn’t have them [levothyroxine tablets]’. (Patient-
24, female, 64 years old)
’I don’t think I’ve ever . . . ever forgotten to take them [levothyroxine tablets].’ (Patient-14,
female, 69 years old)
Perceived benefits of optimal thyroid hormone replacement
Patients felt that their wellbeing and performance had improved with levothyroxine and the majority
of patients felt well regardless of whether their TSH levels were in range or not:
’I think, now that I’m on the levothyroxine, my life is a lot clearer, almost. You know, I haven’t
got that fog, that lack of motivation and that tiredness hanging over me. So dealing with the
condition now I’m medicated for it, to be fair, is a breeze compared to actually living with it
when you don’t realise you’re living with it.’ (Patient-16, female, 37 years old)
Patients that felt well perceived that the personalised approach adopted by their GP had contrib-
uted to making them feel better. This included regular checks of their thyroid function tests and
adjustment of levothyroxine doses to achieve the desired symptom control:
’I get it checked probably more regularly than I’m meant to. And again, once I get it checked,
it’s not the blood test they’ll look at — they’ll [GP] say, “How do you feel? You know, is it . . .?
Do feel any better? Do you feel worse?” And they adjust it according to that.’ (Patient-12,
female, 38 years old)
Generally, patients’ attitude to their disease was positive and they saw the benefit in taking levo-
thyroxine. Patients felt they could live normal lives, and accepted that treatment was permanent:
’It’s so important that you can look around other people who are struggling medically and you
think, well, at least if you’ve got your health. If you’ve got the ability to get out there and enjoy
life, that is so important.’ (Patient-11, male, 68 years old)
’I just accept I’m going to take the tablets for the rest of my life. You know. It’s no big deal,
really.’ (Patient-21, female, 60 years old)
Patient understanding
Generally, patients had poor knowledge of thyroid function, the consequences of poor treatment
adherence, or the risks associated with being out of the therapeutic treatment range, although a few
patients were more informed than others. The perceived requirement for knowledge by a patient
will have been influenced by the perceived threat of hypothyroidism, and the perceived benefit of
optimal thyroid hormone replacement therapy:
’I haven’t an idea. I haven’t any idea how the thyroid works.’ (Patient-20, male, 77 years old)
’But I didn’t think it was a good idea to not be taking the right dosage. So . . . And I don’t know
what would happen if I went in reverse and I didn’t take it [levothyroxine].’ (Patient-15, female,
49 years old)
’Well, my best understanding is I think it [thyroid] produced four hormones, and at least one of
them decays into another. And what they’re doing is topping up one of those hormones with
this thyroxine. Which I believe takes 3 or 4 days to break down anyway. And also that your
thyroid gland is really, really important in your metabolic rate and . . .’ (Patient-22, male,
68 years old)
A barrier to patient understanding was that most patients said that they had not been given infor-
mation at the time of their diagnosis. Although some patients recall receiving a leaflet, generally,
patients did not remember very much about it:
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’I think the key word I can think of is almost “hands-off”. Because obviously my diagnosis was via
the phone. A lot of my blood tests have been, like, either organised or the results given via the
phone. And very, very little face-to-face contact. And no . . . no information.’ (Patient-16, female,
37 years old)
Some patients described that they had done their own research in an attempt to gain informa-
tion. However, poor patient knowledge was exacerbated by the complexity of the information pre-
sented, and patients therefore felt that researching on the internet could be inaccurate and could
provoke anxiety, and were often put off researching:
’Because I’ve spent so much time on Google, essentially. And half the time I don’t know if what
I’m reading is . . . you know. If it’s . . . if it’s wholly accurate or not. If it’s . . . sometimes if it’s
scaremongering or if it’s, you know, just people over exaggerating.’ (Patient-16, female,
37 years old)
The majority of patients with TSH levels outside the reference range were unaware of this. When
followed up it was found that over half of these patients were being over-replaced (low TSH)
(Table 1). Patients who are over-replaced may be asymptomatic and therefore unaware of their
over-suppressed TSH level.
Perceived barriers of optimal thyroid hormone replacement
Patients that had a normal TSH result but still felt unwell thought that their symptoms were being
ignored by their GP or assumed them to be unrelated to their thyroid condition, and felt that their
good TSH result presented a barrier to optimising their treatment. An empathetic and holistic
approach as suggested by Patient-8 may prove more beneficial in identifying and resolving these
symptoms rather than a singular focus on TSH as a measure of wellbeing:
’I just feel that as long as you’re within the range, no matter how close to the cusp — as long as
you’re within the range, they go “Just leave you at that.” They don’t look at the symptoms
you’re having or the, you know . . . the battles that you’re having. You know?’ (Patient-4, female,
62 years old)
’I think it’s . . . It could probably be monitored better by looking at the whole . . . At the patient.
And when things are normal, I think we’ve got to remember that that’s just an average. And
everyone is . . . What might be normal for me, might not be . . . you know, it’s different for
everyone.’ (Patient-8, female, 63 years old)
Patients that felt unwell also believed that TSH levels were too crude a measure to gauge optimal
thyroid hormone replacement. Some more informed patients had approached their GP and asked
for further tests to check their triiodothyronine (T3) and thyroxine (T4) readings, as they felt unwell
and dissatisfied with their treatment. However, since T3 measurements have limited value in the
management of hypothyroidism,32 these tests are not routinely offered:
’When I’ve mentioned previously about associated conditions that . . . And the T3, I was met
with the fact that everything else looked normal — therefore there was no need to do other
investigations. Which I find . . . I do find that quite sad, actually. Because, yes, then it does make
you feel like you’re not cared enough about.’ (Patient-5, female, 47 years old)
Patients perceived that tiredness and memory problems could be due to aging, inadequate
sleep, or from having a long day rather than specifically related to their hypothyroidism. Patients
with symptoms such as cold extremities and dry skin felt that they had always had these problems
and so were unsure if they could relate it directly to their thyroid. Lack of understanding of their con-
dition and uncertainty regarding the cause of their symptoms may present as a barrier to further dis-
cussion with their GP to address these symptoms and improve wellbeing:
’It’s like, you know, I’ve got an 8-month old. She still wakes up on her own schedule. And, like,
so am I tired in the morning because she’s had a . . . like, she’s got up an extra time or just taken
that little bit longer to settle. Or am I tired because it’s a thyroid? The thyroid is so difficult.’
(Patient-16, female, 37 years old)
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The majority of patients felt their thyroid was the cause of their symptoms, however, two patients
perceived that symptoms might be attributable to a health problem other than hypothyroidism.
Moreover, after a thyroid function test, one of these patients felt her symptoms were a result of
another health concern:
’I’ve lately had a lot of symptoms, which led to me getting my thyroid re-checked and . . . which
is . . . moving on to, like, looking at other causes. Where I have got a lot of, like, tiredness,
headaches, stiffness in hands and feet. So I don’t believe it’s currently down to the thyroid.’
(Patient-16, female, 37 years old)
’You can’t blame everything on the thyroid, you see. Because you could have something . . . your
heart . . . or something like that.’ (Patient-27, male, 58 years old)
The GP or endocrinologist was generally seen as responsible for achieving adequate thyroid hor-
mone replacement, rather than patients themselves. Some patients reported that they felt that there
was a lack of consensual decision making between them and their GP, and this may present a barrier
to optimising thyroid control if patients felt their GP could improve their treatment, but did not want
to contradict their doctor. Moreover, some patients reported that they had not asked for advice or
mentioned their symptoms as they did not want to ‘bother’ their GP:
’It is my responsibility, I know that, for my health and wellbeing and everything. But it’s up to the
doc, because it’s a tablet, isn’t it? It’s not taking two paracetamol. It’s up to the doctor to tell
me what I should be doing. I don’t know if that’s right or not, but that’s what I feel anyway.’
(Patient-24, female, 64 years old)
’Well, let me put it this way. I think if they’ve qualified to be a doctor, or a nurse, they . . . In my
opinion, sometimes — not always, but sometimes — know better than me. Because they’ve
got all the information at their fingertips. I haven’t.’ (Patient-19, female, 71 years old)
’I’m not embarrassed about the fact that I’ve got this and got that. I’m not shy about that. But
you just feel, oh . . . I’m bothering them.’ (Patient-4, female, 62 years old)
Ability to act
Experience of symptoms was a cue to action seen from the data. Patients who were still experienc-
ing symptoms, even those with a normal TSH result which was a perceived barrier to optimal thyroid
control, felt disheartened and frustrated about their wellbeing but continued to take their levothyr-
oxine as they felt it made some improvement:
’It is. It is — it’s really frustrating because you think that some people lose weight so quickly.
But, I mean, it’s taken me since January to get 2 stone off.’ (Patient-1, female, 36 years old)
Using a tablet box, keeping their levothyroxine in a visible or daily accessed place such as by the
coffee, in their makeup bag, by their bed or next to their toothbrush, or having a family member
reminding them were strategies that patients used to reduce the risk of non-adherence to levothyr-
oxine and avoid suboptimal treatment:
’They’re in a little bag in that chest of drawers. And that’s the first job every morning, to take my
tablets and get my mascara on. It’s all in the same bag, so . . .’ (Patient-21, female, 60 years old)
Some patients reported receiving thyroid treatment promoting advice from their pharmacist such
as regarding timing of medication, avoiding food and other medication. Additionally, most patients
felt that if they needed help such as accidental overdosing or if they thought they needed their dose
altering or were not feeling well they would ask their GP:
’What he has done, and I think annually now — so just the last 2 years — when I’ve gone in, he
says, “Do you have a few minutes, just to go over your medication?” So he [pharmacist] checks
how I am.’ (Patient-23, male, 69 years old)
’I know that I can go to the doctors and get the medication to control it.’ (Patient-2, female,
85 years old)
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Readiness to act
Few patients were unhappy to take levothyroxine every day, but were aware they needed to. One
patient had negotiated with her GP to take 50 rather than 100 mg/day as she did not like medication
and preferred homeopathy, demonstrating aspects of negotiating preferences with medication tak-
ing and shared decision making:
’Really she [GP] would be happier if I took 100 mgs. And that was when I said, well, would it be
dangerous if we keep it to 50? And she said no. And I said, “Well, I would like to keep it at 50”.’
(Patient-26, female, 68 years old)
Patients with TSH levels within range that reported feeling symptomatic had researched alterna-
tives to levothyroxine, such as armour thyroid (desiccated porcine thyroid extract), combination ther-
apy with liothyronine (synthetic T3), and homeopathic options in an attempt to find something to
further relieve symptoms. However, patients did not recount speaking to their GP about an alterna-
tive, and one patient mentioned that she thought it was pointless to ask her GP about armour thy-
roid as her requests for T3 and T4 readings had previously been rejected, highlighting the lack of
shared decision making that was previously identified as a barrier to optimal thyroid hormone
replacement:
’Yeah. And I thought it was pointless going to my doctor about that [armour thyroid].’ (Patient-
8, female, 63 years old)
Discussion
Summary
Perception of disease threat was high in patients in this study that had experienced hypothyroid
symptoms at diagnosis, and this was evident from reported excellent levothyroxine adherence.
Improved wellbeing and performance, and the ability to cope with the condition were the perceived
benefits of optimal thyroid hormone replacement. Poor patient knowledge of thyroid hormone
replacement was likely due to lack of credible information, and was influenced by perceived threat
of disease and assumed benefits. Barriers included lack of patients’ authority to challenge the GP,
uncertainty regarding the significance of their symptoms, and over-reliance on TSH within the refer-
ence range as the sole measure of adequate thyroid hormone replacement. The ability to act was
influenced by experience of symptoms and shown by strategies to promote drug adherence, while
patient readiness to act was demonstrated by negotiation of their medication preferences and/or
seeking alternatives to levothyroxine in patients that did not feel well replaced.
Strengths and limitations
By using in-depth discussions with patients in the absence of any healthcare professional
it was possible to gather rich data of the personal thoughts and feelings of patients with hypothy-
roidism. However, it is possible that the perspectives of the researcher led to bias, influencing how
the patients responded to the questions in the interviews or data analysis. As the interviewer did not
have a clinical background or strong prior assumptions, it is unlikely that interviewer bias would have
influenced these results.
The participants were sampled from 11 GP practices in a single locality in the UK and
therefore caution about generalising these findings to other populations and healthcare
settings is needed. Over half of patients with suboptimal thyroid hormone replacement had TSH val-
ues lower than the reference range. Interviewing more patients with high TSH may have given differ-
ent outcomes. However, the authors aimed to study a broad sample of patients with hypothyroidism
including well-controlled, overtreated, and undertreated patients, in order to obtain insights across
a range of thyroid statuses. As the results demonstrate, some patients with suboptimal thyroid hor-
mone replacement were satisfied with their treatment while other patients with normal TSH
remained unwell.
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Comparisons with existing literature
Similar to the current study, in previous qualitative research, patients with hypothyroidism described
tiredness as the most common symptom they had experienced, and lack of information exchanged
between patient and doctor was also acknowledged.33
Additionally, the vague nature of hypothyroid symptoms often lead to dissatisfaction in patients
and symptoms being discounted or blamed on other causes by patients and health
professionals.33,34
Studies have demonstrated that enhanced knowledge about disease can lead to a higher per-
ceived involvement in medical decisions,35,36 and may be highly influential in improving compli-
ance.36 Lack of shared decision making (SDM) was a barrier identified in the current study. In a
qualitative study by Britten et al,37 a lack of SDM in GP consultations was found to be influenced by
patients not voicing agenda items, aversion to taking medicine or requests for medication, and mis-
understandings were seen by both patient and GP. Moreover, in instances where patients did voice
their concerns, this was often unexplored by their doctor. With this in mind, increasing SDM in
patients with hypothyroidism may help optimise treatment, similar to that in patients
with hypertension where improved blood pressure control and adherence was seen in patients
involved in SDM.38
Previous studies using questionnaires have found a reduction in neurocognitive functioning, psy-
chological wellbeing, and quality of life in levothyroxine treated patients with normal TSH levels
compared to population reference standards39 or age- and sex-matched controls.40 The current
study thus highlights the barriers faced by such patients in achieving wellbeing, including uncertainty
regarding the significance of their symptoms, fear of challenging their GP’s attitude, and the over-
reliance on biochemical indices by health professionals.
Patients who have persistent symptoms despite a TSH concentration within the reference range
should be carefully evaluated for other causes of their symptoms including a range of comorbidities
and lifestyle factors.41 Surks et al acknowledged that GPs should have an individualist approach to
each patient as the TSH reference range applies to populations,42 supporting over-reliance on TSH
levels as a barrier to optimal thyroid replacement for each patient. Additionally, previous research
has shown that some patients feel better being slightly over-treated,43 although persistently very
low or fully suppressed TSH levels (0.03 mU/L) can increase the risk of cardiovascular events and
fractures.11
Other health belief studies have found a strong link between high perceived threat of chronic dis-
ease and good patient medication adherence.44,45 For hypothyroidism, non-adherence to levothyr-
oxine therapy has been reported to be as low as 22%,46 but the traditional belief that poor
adherence causes suboptimal thyroid treatment was not supported by this study.
Implications for future research and clinical practice
Although levothyroxine therapy will return TSH levels to within the normal range, this range is wide
and it can be difficult to ascertain an individual’s optimal TSH set-point. Thus the use of TSH refer-
ence range and the role of symptom control require further investigation. However, the cost-effec-
tiveness of these strategies and the cardiovascular and osteoporosis risks that are associated with
very low TSH levels should be considered.
Implementing the provision of standardised information at the time of diagnosis such as leaflets
from patient.co.uk, which this study’s cohort reported not receiving, having a medication review
with their pharmacist, or directing patients to patient support groups, such as the British Thyroid
Foundation, may help to improve patient knowledge and understanding, reduce uncertainty of
symptoms and promote GP and patient SDM. However, use of an educational booklet during a
randomised controlled trial showed no benefits on levothyroxine adherence or wellbeing in patients
with hypothyroidism.47 Thus, whether benefits from educational interventions can be achieved within
routine practice will require further research. Structured education has proved successful in other
chronic disease models, such as diabetes mellitus, and similar models could be adapted in patients
with hypothyroidism.
Investigating the perceptions of health professionals involved in the management of hypothyroid-
ism is crucial, particularly the responsiveness to patient’s symptoms, over-reliance upon TSH levels,
and the community pharmacist’s role. Focusing on the synergy of patient concerns, the dose and
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time of administration of levothyroxine, the dietary advice given, and the role of the GP have been
described to be key to ensuring the appropriate therapeutic outcome of levothyroxine.48 Following
on from this, systematically quantifying the effect of concomitant medication, timing of administra-
tion and interference from diet on the bioavailability of levothyroxine may further inform hypothyroid
treatment strategies. Lastly, there is now a growing interest in the effect of pharmacogenomic fac-
tors on wellbeing in patients with hypothyroidism. Common genetic variations in the DIO2 deiodi-
nase gene involved in thyroid hormone action have been linked with impaired psychological
wellbeing in subgroups of patients on levothyroxine, but further studies are required to confirm this
association and whether alternative treatment with liothyronine will benefit such groups of
patients.49
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